ABBVIE INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25 CAD | +1.46% |
|
+0.36% | +10.28% |
| 06-28 | Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU | MT |
| 06-28 | AbbVie, Genmab Receive Positive European Opinion on Marketing Authorization for Possible Lymphoma Treatment | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 815B | ||||||
| 641B | ||||||
| 352B | - | - | - | - | ||
| 314B | ||||||
| 242B |
